Opipramol

DB12930InvestigationalSmall molecule

Opipramol is a medication to treat general anxiety and somatoform disorders. Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

Chemical structure of Opipramol
Mechanism
Curator reviewed
Formula / weight
C23H29N3O · 363.505 g/mol (avg)

Resolves to

Compound
UNIID23ZXO613CCAS315-72-0ChEMBLCHEMBL370753ChEBI94614PubChem9417
Clinical / RWD
RxNorm7674ATCN06AA05PharmGKBPA144614922
Structure
InChIKeyYNZFUWZUGRBMHL-UHFFFAOYSA-NSMILESOCCN1CCN(CCCN2C3=CC=CC=C3C=CC3=CC=CC=C23)CC1
Targets
Q99720SIGMAR1P35367HRH1Q5BJF2TMEM97P28223HTR2AP14416DRD2

What you can answer from here — as of August 30, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,354Drug interactionsStructured to mechanism, not free text
Sign in
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
14ContraindicationsEach with its own population and attribute set
Sign in
81Marketed productsAcross 4 countries and 6 labellers
Sign in
1ATC codeIncluding every combination product, plus 19 drug categories
Sign in
14+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Opipramol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In